OncoMatch/Clinical Trials/NCT07228832
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Is NCT07228832 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Drug: Ivonescimab and Drug: Bevacizumab for metastatic colorectal cancer (crc).
Treatment: Drug: Ivonescimab · Drug: Bevacizumab — A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer(HARMONi-GI3)
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Excluded: BRAF v600e
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immunotherapy
Cannot have received: anti-angiogenic therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Clinical Study Site · Goodyear, Arizona
- Clinical Study Site · Beverly Hills, California
- Clinical Study Site · Cerritos, California
- Clinical Study Site · Corona, California
- Clinical Study Site · Duarte, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify